FDA To Seek More Power Over Compounders At Hearing

By Rachel Slajda (November 13, 2012, 8:04 PM EST) -- The U.S. Food and Drug Administration will make the case to Congress on Wednesday that it should have more authority over compounding pharmacies, but it is likely to be met with skepticism over how well it used its existing oversight of the compounder tied to a recent deadly meningitis outbreak.

At the first congressional hearing over the meningitis outbreak, to be held Tuesday by the House Energy and Commerce Committee's oversight subcommittee, FDA Commissioner Margaret Hamburg is expected to testify that the FDA should have more power to regulate compounding pharmacies.

Regulation of such pharmacies, which create custom drugs for patients...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!